These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32055804)

  • 61. Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up.
    Ludwig R; Malla B; Höhrhan M; Infante-Duarte C; Anderhalten L
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203434
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sphingosine 1-Phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated Aplastic Anemia in a Mouse Model.
    Komiya T; Gohda M; Shioya H; Katsumata S
    J Pharmacol Exp Ther; 2021 Feb; 376(2):250-260. PubMed ID: 33257316
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sphingosine 1-phosphate receptor modulators in multiple sclerosis.
    Subei AM; Cohen JA
    CNS Drugs; 2015 Jul; 29(7):565-75. PubMed ID: 26239599
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
    Kihara Y; Chun J
    Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
    [TBL] [Abstract][Full Text] [Related]  

  • 65. S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal.
    Stamatellos VP; Rigas A; Stamoula E; Lallas A; Papadopoulou A; Papazisis G
    Mult Scler Relat Disord; 2022 Mar; 59():103681. PubMed ID: 35168096
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
    Hach T; Shakeri-Nejad K; Bigaud M; Dahlke F; de Micco M; Petricoul O; Graham G; Piani-Meier D; Turrini R; Brinkmann V; Nicoletti F
    J Interferon Cytokine Res; 2023 Jun; 43(6):246-256. PubMed ID: 36454249
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Siponimod (Mayzent)--a new drug for multiple sclerosis.
    Med Lett Drugs Ther; 2019 May; 61(1571):70-72. PubMed ID: 31169805
    [No Abstract]   [Full Text] [Related]  

  • 69. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM; Oh J
    Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review.
    Li Q; Jing LJ; Li Y; Jia Y
    BMC Neurol; 2023 Jul; 23(1):286. PubMed ID: 37525104
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Short- and long-term effects of siponimod on autonomic nervous system in secondary progressive multiple sclerosis.
    Habek M; Junaković A; Karić A; Crnošija L; Barun B; Gabelić T; Adamec I; Krbot Skorić M
    Mult Scler Relat Disord; 2022 Aug; 64():103966. PubMed ID: 35724530
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
    Gilmartin CG; Hoyle N; Garjani A; Dixon T; Jos H; Paling D; Brownlee W; Tench C; Evangelou N
    Mult Scler; 2024 Apr; 30(4-5):600-604. PubMed ID: 38323423
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis.
    Habek M; Crnošija L; Junaković A; Adamec I; Barun B; Gabelić T; Krbot Skorić M
    Clin Neurophysiol; 2021 Feb; 132(2):581-585. PubMed ID: 33461086
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients.
    Sharma K; Chaudhary D; Beard K; Srivastava S; Khalid SH; Sriwastava S
    Mult Scler Relat Disord; 2022 Mar; 59():103675. PubMed ID: 35168095
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
    Coyle PK; Freedman MS; Cohen BA; Cree BAC; Markowitz CE
    Ann Clin Transl Neurol; 2024 Apr; 11(4):842-855. PubMed ID: 38366285
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
    Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.
    Ward LA; Lee DS; Sharma A; Wang A; Naouar I; Ma XI; Pikor N; Nuesslein-Hildesheim B; Ramaglia V; Gommerman JL
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821174
    [TBL] [Abstract][Full Text] [Related]  

  • 79. First
    Starke L; Millward JM; Prinz C; Sherazi F; Waiczies H; Lippert C; Nazaré M; Paul F; Niendorf T; Waiczies S
    Theranostics; 2023; 13(4):1217-1234. PubMed ID: 36923535
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Siponimod for Cognition in Secondary Progressive Multiple Sclerosis: Thinking Through the Evidence.
    Leavitt VM; Rocca M
    Neurology; 2021 Jan; 96(3):91-92. PubMed ID: 33328322
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.